MM has been shown to be a phenotypically heterogeneous malignancy, with numerous sub-clones within the same patient [19–21], which may increase the risk of failure from single-antigen therapies; another cause of recurrence may be a loss of BCMA expression on malignant plasma cells. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.